2024-10-13 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**1. Performance Comparison:**

Regeneron Pharmaceuticals Inc. (REGN) is a biotechnology company that develops and commercializes life-saving medicines for serious diseases. Compared to the S&P 500 (VOO), REGN has underperformed in the past, with a cumulative return of 93.48% compared to the S&P 500's 135.82%. This represents a current divergence of -42.34%, which is 33.67% of the historical range.

**2. Recent Price Movements:**

The recent price movements indicate a possible downward trend. The closing price is 1015.67, lower than the 5-day moving average (1005.86). Additionally, it's also below the 20-day (1059.31) and 60-day moving averages (1108.75), indicating a potential downtrend.

**3. Technical Indicators:**

The RSI (31.62) indicates the stock is currently in oversold territory, suggesting a potential rebound. However, the PPO (-0.34) remains negative, indicating weakness in the short term. The recent relative divergence of -25.78 suggests a short-term downward trend. The expected return for REGN is 0%, signifying no anticipated excess return over the S&P 500 (VOO) in the next five years.

**4. Recent Earnings and Outlook:**

Regeneron's most recent earnings report showed EPS of 13.25 and revenue of 3.55B$. This surpassed the analyst consensus estimate of 12.87 for EPS and 3.45B$ for revenue.

| Date        | EPS     | Revenue    |
|-------------|---------|-------------|
| 2024-08-01  | 13.25   | 3.55 B$     |
| 2024-05-02  | 6.7     | 3.15 B$     |
| 2023-11-02  | 9.48    | 3.36 B$     |
| 2023-08-03  | 9.05    | 3.16 B$     |
| 2024-08-01  | 9.05    | 3.16 B$     |

Overall, REGN's recent earnings performance has been positive, exceeding expectations. However, the company faces competition from other biotechnology companies and the possibility of regulatory challenges.

**5. News and Recent Issues:**

Recent market outlook for REGN suggests a mixed sentiment. While the company's strong earnings and pipeline have been acknowledged, concerns remain regarding the potential impact of increased competition, regulatory scrutiny, and a potential economic downturn on the pharmaceutical industry.

Analysts have mixed opinions on REGN. Some analysts are optimistic about the company's long-term growth potential, citing its strong pipeline of promising drugs and its focus on developing innovative therapies. However, others are more cautious, noting the competitive landscape and the potential for regulatory challenges.

**6. Overall Analysis:**

While REGN's recent earnings performance has been positive, its overall performance has been lagging behind the S&P 500. Recent price movements and technical indicators suggest a potential downtrend in the short term. The expected return is 0%, indicating no anticipated excess return over the S&P 500 (VOO) in the next five years.

**7. Conclusion:**

Regeneron Pharmaceuticals Inc. (REGN) faces a mixed outlook. While its recent earnings have been strong, the company's future success depends on overcoming challenges in the competitive biotech landscape and navigating regulatory hurdles. Investors should consider these factors, along with the current market conditions, before making investment decisions.